Focus: Cancer Center Featured Story 2

Filters close
Released: 27-Feb-2020 1:15 PM EST
Memorial Sloan Kettering Awards & Appointments
Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

Released: 24-Feb-2020 1:20 PM EST
Combined therapy may improve clinical responses for endometrial, colorectal and gastric tumors
University of Texas M. D. Anderson Cancer Center

Combined therapy may improve clinical responses for endometrial, colorectal and gastric tumors. Enzyme inhibitor with anti-PD1 checkpoint blockade boosted efficacy over either treatment alone

Released: 27-Feb-2020 8:35 AM EST
NCCN 2020 Annual Conference to Examine Advances in Cancer Care and Emerging Issues in Oncology
National Comprehensive Cancer Network® (NCCN®)

Cancer care providers will gather in Orlando on March 20-22 for the National Comprehensive Cancer Network® (NCCN®) 2020 Annual Conference: Celebrating 25 Years of NCCN. The three-day, in-person conference features more than 30 educational sessions on state-of-the-art practices in cancer care.

Released: 26-Feb-2020 10:25 AM EST
The Tri-Institutional Therapeutics Discovery Institute, Inc. Renews Partnerships with Takeda and Bridge Medicines, LLC
Memorial Sloan Kettering Cancer Center

To date, work done within the Tri-I TDI has resulted in the launch of two New York City–based companies and the licensing of six therapeutic discovery programs.

Released: 25-Feb-2020 3:05 PM EST
KU Cancer Center partners with Fox4 to host Teen Town Hall on Vaping
University of Kansas Cancer Center

The University of Kansas Cancer Center has partnered with Fox4 and the Kansas City Kansas School district to host a town hall on vaping at Sumner Academy February 27.

Newswise: Validating NIH Toolbox to help evaluate cognitive processing in people with intellectual disability
Released: 24-Feb-2020 4:00 PM EST
Validating NIH Toolbox to help evaluate cognitive processing in people with intellectual disability
UC Davis Health

Cognitive processing in people with intellectual disability can now be accurately assessed thanks to UC Davis Health researchers who updated and validated series of tests, part of the NIH Toolbox Cognitive Battery.

Newswise: Osteosarcoma profiling reveals why immunotherapy remains ineffective
Released: 20-Feb-2020 2:55 PM EST
Osteosarcoma profiling reveals why immunotherapy remains ineffective
University of Texas M. D. Anderson Cancer Center

Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally poor responses observed from treatment with immune checkpoint inhibitors, according to new research from The University of Texas MD Anderson Cancer Center.

Newswise: MD Anderson announces strategic collaboration with Denali Therapeutics to research and develop targeted therapies for neurodegenerative diseases
Released: 20-Feb-2020 4:15 PM EST
MD Anderson announces strategic collaboration with Denali Therapeutics to research and develop targeted therapies for neurodegenerative diseases
University of Texas M. D. Anderson Cancer Center

MD Anderson announces a strategic research collaboration with Denali Therapeutics to develop new targeted therapies for Alzheimer's and other neurodegenerative diseases.

Released: 20-Feb-2020 12:40 PM EST
Yale Cancer Center Study Shows Long-Term Survival Benefit for Certain Patients with Advanced Lung Cancer
Yale Cancer Center

According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).

Newswise: Addition of Immunotherapy to Standard Treatment for Advanced Stage Non-Small Cell Lung Cancer is Safe and Tolerable as First-Line Therapy
Released: 18-Feb-2020 4:05 PM EST
Addition of Immunotherapy to Standard Treatment for Advanced Stage Non-Small Cell Lung Cancer is Safe and Tolerable as First-Line Therapy
Rutgers Cancer Institute of New Jersey

Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment (chemoradiation) is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer (NSCLC).



close
Chat now!
1.58664